• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 25th September 2019

Can Conventional Blood Tests Predict Future Disability Risks?

New research published in Economics and Human Biology demonstrates that elevated blood tests and nurse-collected physical measures predict progression to disability two to four years ahead for individuals without a disability history. In a new study, published in Economics and…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

New research published in Economics and Human Biology demonstrates that elevated blood tests and nurse-collected physical measures predict progression to disability two to four years ahead for individuals without a disability history.

In a new study, published in Economics and Human Biology, Apostolos Davillas and Steve Pudney (University of Sheffield) demonstrate that elevated blood tests and nurse-collected physical measures predict progression to disability at two to four years.

The wider social impacts of ill-health – on quality of life, personal and social functioning, and social costs of disease – depend critically on the duration and severity of disability. Disability is associated with loss of employment and serious consequences for families. It typically implies long-lasting impairments that may prevent independent living and generate substantial public costs. This is particularly so in the UK, where disability prevalence is above the European Union average and has risen rapidly from 11.9 million in 2013/14 to 13.3 million in 2015/16. A crucial question for researchers and policymakers is whether the demand for care services will be curbed by gains in disability-free life expectancy, alongside the projected continuing gains in longevity. An answer to this question requires a better understanding of the processes leading to disability, allowing the development of strategies and screening programmes to address disability more efficiently.

The study examines the predictive power of a wide range of biomarkers for future disability risks, over and above the potential role of conventional measures of self-assessed health (SAH). Applying nationally representative, longitudinal U.K. data (Understanding Society), the study followed a cohort of individuals without disability history at baseline to estimate predictive models for disability two to four years ahead. To explore the robustness of the results, the study considers alternative disability measures, ranging from the number of functional difficulties reported to the receipt of disability benefits. We found a quantitatively and statistically significant predictive role for a large set of nurse-collected and blood-based biomarkers.

In subsequent analyses, we develop latent variable models to identify any distinct dimension of health that predicts future disability and is captured by the biomarkers but missed by the conventional SAH measures. We found that, although SAH has performed well, it was far from perfect as a leading indicator for disability risks. SAH tended to underrepresent grip strength, lung and liver function, and stress-related steroid hormone levels, while overemphasising adiposity, hypertension, and cholesterol levels. These results highlight the presence of distortions in SAH, in the sense of dimensions of health that are given too much or too little weight by SAH in predicting disability.

The publication of the study is timely, given the UK government’s recent prevention green paper. Our study provides novel insights on targeting certain population groups at risk of disability progression and tackling the relevant future public costs. To support this, exclusive reliance on self-reported subjective measures should be avoided. Our project demonstrates scope – for physical health, at least – for wider use of objective measures of health (including blood-based biomarkers) by social scientists, health economists, and policymakers.

Citation

Davillas, A., & Pudney, S., 2019. Biomarkers as precursors of disability. Economics & Human Biology. DOI. RePEc.

  • Research
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!